Cargando…
Effectiveness of modified Buzhong Yiqi decoction in treating myasthenia gravis: study protocol for a series of N-of-1 trials
BACKGROUND: Myasthenia gravis (MG) is an acquired autoimmune disease with high heterogeneity. The disease is chronic, relapsing repeatedly and progressive with acute exacerbation occasionally. Although the treatment of MG has developed, it is still unsatisfactory and has some unexpected side effects...
Autores principales: | Weng, Senhui, Li, Jinghao, Chen, Benshu, He, Long, Zhong, Zhuotai, Huang, Linwen, Zhang, Shijing, Liu, Fengbin, Jiang, Qilong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9044679/ https://www.ncbi.nlm.nih.gov/pubmed/35477531 http://dx.doi.org/10.1186/s13063-022-06287-9 |
Ejemplares similares
-
Modified Buzhong Yiqi decoction for myasthenia gravis: A systematic review protocol
por: Jiang, Xiaotao, et al.
Publicado: (2018) -
Therapeutic efficacy and immunoregulatory effect of Qiangji Jianli Capsule for patients with myasthenia gravis: Study protocol for a series of randomized, controlled N-of-1 trials
por: Weng, Senhui, et al.
Publicado: (2020) -
Astragaloside IV ameliorates experimental autoimmune myasthenia gravis by regulating CD4 + T cells and altering gut microbiota
por: Weng, Senhui, et al.
Publicado: (2023) -
Effect of Buzhong Yiqi decoction on anti-acetylcholine receptor antibody and clinical status in juvenile ocular myasthenia gravis
por: Li, Jiaduo, et al.
Publicado: (2021) -
Evaluation of the Quantitative Myasthenia Gravis Score and Grip Strength in Chinese Patients With Myasthenia Gravis: An Observational Study
por: Li, Jinghao, et al.
Publicado: (2021)